Spanish company Almirall has formed a research alliance with BioFocus, an integrated drug discovery specialist based at the heart of the Cambridge UK BioMedTech cluster.The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. The collaboration could be worth €7.5m to BioFocus.
BioFocus will apply its integrated drug discovery capabilities whilst Almirall will bring in respiratory specific knowhow to the joint experimental effort.
“We selected BioFocus for this alliance because of the excellent technology and scientific fit between both companies,” said Dr Bertil Lindmark, CSO, executive director R & D of Barcelona-based Almirall.
BioFocus MD, Dr Chris Newton, said the company was thrilled to form a drug discovery alliance with one of Europe’s leading research-based pharmaceutical companies.
Respiratory is a key research focus for Almirall together with gastrointestinal and dermatology areas where the company is especially engaged to offer new therapeutic solutions.
Almirall’s products are currently in over 70 countries while it has direct presence in Europe and Latin America through 12 affiliates.
BioFocus provides integrated drug discovery that delivers pre-clinical drug candidates in all therapeutic areas with strong capability in neurodegenerative diseases, inflammatory diseases and with a growing track record of delivering candidates against rare and neglected diseases.
The company employs over 220 scientists at its three research centres in the UK, Switzerland and the Netherlands.